Skin pharmacology and physiology · 2025
Healing Diabetic Foot Ulcers with Topical Timolol Improves Healed Epithelial Integrity.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lyle Rawlings E, Dafinone Mirabel E, Lim Pallas, Budhiraja Anuj, Mehta Alisha, Dahle Sara E, Isseroff Roslyn Rivkah
Аннотация
INTRODUCTION: Diabetic foot ulcers (DFUs) are a common complication in diabetes, leading to high amputation risk and significant healthcare costs. Given topical timolol's emergence as a potential wound-healing agent, our study explored its impact on epidermal integrity.
METHODS: This study was a post hoc analysis conducted as part of a randomized controlled trial at the Veterans Affairs Northern California Health Care System. Twenty patients, who had DFUs healed in the original trial, 10 in the timolol arm, and 10 in the placebo arm, were enrolled in the study. The primary outcome was transepidermal water loss, measured monthly for 3 months of post-healing using a closed-chamber device. The secondary outcome was re-ulceration rates over 1 year.
RESULTS: Transepidermal water loss at 1, 2, and 3 months of post-healing was significantly lower in the timolol group than in the placebo group (p < 0.01). Linear mixed models identified contralateral foot transepidermal water loss as a significant predictor of healed diabetic foot ulcer site transepidermal water loss (estimate = 0.76, p < 0.001). The interaction between timolol treatment and months since healing significantly reduced transepidermal water loss over time (estimate = -2.2, p = 0.002). The use of a wheelchair was also associated with a significant decrease in transepidermal water loss (estimate = -7.7, p = 0.01). Initial transepidermal water loss values were higher in patients who re-ulcerated, but the difference was not statistically significant (p = 0.42). There was no difference in re-ulceration rates in this small pilot study.
CONCLUSION: Topical timolol significantly improved skin barrier function in healed DFUs, reducing transepidermal water loss. Although re-ulceration rates were not significantly different, the trend suggests potential benefits. Further studies with larger sample sizes and longer follow-up are needed to confirm these findings and explore transepidermal water loss's predictive value for re-ulceration.
METHODS: This study was a post hoc analysis conducted as part of a randomized controlled trial at the Veterans Affairs Northern California Health Care System. Twenty patients, who had DFUs healed in the original trial, 10 in the timolol arm, and 10 in the placebo arm, were enrolled in the study. The primary outcome was transepidermal water loss, measured monthly for 3 months of post-healing using a closed-chamber device. The secondary outcome was re-ulceration rates over 1 year.
RESULTS: Transepidermal water loss at 1, 2, and 3 months of post-healing was significantly lower in the timolol group than in the placebo group (p < 0.01). Linear mixed models identified contralateral foot transepidermal water loss as a significant predictor of healed diabetic foot ulcer site transepidermal water loss (estimate = 0.76, p < 0.001). The interaction between timolol treatment and months since healing significantly reduced transepidermal water loss over time (estimate = -2.2, p = 0.002). The use of a wheelchair was also associated with a significant decrease in transepidermal water loss (estimate = -7.7, p = 0.01). Initial transepidermal water loss values were higher in patients who re-ulcerated, but the difference was not statistically significant (p = 0.42). There was no difference in re-ulceration rates in this small pilot study.
CONCLUSION: Topical timolol significantly improved skin barrier function in healed DFUs, reducing transepidermal water loss. Although re-ulceration rates were not significantly different, the trend suggests potential benefits. Further studies with larger sample sizes and longer follow-up are needed to confirm these findings and explore transepidermal water loss's predictive value for re-ulceration.